The Hunt for the Next 10 Bagger

[BioSpecialist]

TNXP (MC $33 M) (Cash $34 M) Shares Out 7.5 M // Phase 3 Data in 1H 2018 = 1000%++ UPSIDE Potential !

Ultra Low float Gem / Trading below Cash/ Phase 3 Data in 1H 2018 //$650 Million Potential for the Drug /Stock should be at $15 right now and sky is limit on positive phase 3 outcome = A MUST HAVE .GLTA

Tonix Pharma (TNXP)

Market Cap: $33 Million
Cash: $34.5 Million
Kurs: $4.50

Shares Out: 7.5 Million

New Presentation
http://content.equisolve.net/tonixpharma/media/5834b932b328c4417b28ea179cb3f7c8.pdf

Phase 3 HONOR study of Tonmya in military-related PTSD enrolling
•Encouraging evidence of safety and efficacy was demonstrated in Phase 2

Breakthrough Therapy designation from U.S. Food and Drug Administration (FDA)
•Expedited development and accelerated review are expected
•Potential to file NDA based on one Phase 3 study if data are statistically persuasive

Proposed registration plan agreed by the FDA
•Additional nonclinical safety and clinical abuse potential studies are not required

Patent protection through 2034 in U.S.
•Composition of matter patent for eutectic, required for transmucosal delivery of cyclobenzaprine